Adipolin and IL-6 Serum Levels in Chronic Obstructive Pulmonary Disease

HIGHLIGHTS: What are the main findings? This study showed reduced adipolin serum levels as a pro-inflammatory molecule in COPD patients. Serum adipolin levels correlate with serum levels of IL-6, exercise capacity (based on mMRC dyspnea score), and quality of life (based on CAT score). What is the implication of the main finding? Imbalance in the serum levels of pro-inflammatory and anti-inflammatory markers in COPD patients. Correlation between pro-inflammatory and anti-inflammatory markers with disease severity and quality of life in COPD patients. ABSTRACT: Objective(s): One of the adipokines that have insulin-sensitizing properties is adipolin, whose reduced levels have been reported in obesity, oxidative stress, and inflammation. The present study investigated serum interleukin-6 (IL-6) and adipolin levels in chronic obstructive pulmonary disease (COPD) patients. Method: A control case study included 60 COPD patients and 30 healthy subjects in the research and measured adipolin and IL-6 serum levels. In addition, serum adipolin levels in COPD patients were assessed according to the GOLD grade. The relationship between serum adipolin levels and study variables were also analyzed. Results: The results showed reduced adipolin levels in COPD patients compared with healthy individuals (p < 0.001). Furthermore, increased levels of IL-6 were evident in the COPD group compared to the control group (p < 0.001). Adipolin serum levels were positively correlated with PFTs and negatively correlated with IL-6 levels. Conclusion: Decreased adipolin levels enhanced disease severity in COPD patients. It seems that the existence of a significant relationship between adipolin and IL-6 may indicate the role of adipolin in the pathophysiology of COPD.